IGEL has secured an investment from Vitruvian Partners, bringing its valuation to over $1 billion. Existing investor TA Associates remains on board. The deal is expected to close in the first quarter of 2027.
As an international investor, Vitruvian Partners focuses on fast-growing companies and is now joining TA Associates as an investor in IGEL. IGEL has not disclosed the exact investment amount. However, the company’s valuation now clearly exceeds $1 billion. This makes IGEL a unicorn.
Annual recurring revenue (ARR) grew by more than 40 percent last year. The new capital will fund product development, the partner ecosystem, and international expansion. “Our growing adoption by large international enterprises and governments demonstrates both the strength of our technology and the scale of the opportunity ahead,” says CEO Klaus Oestermann.
TA Associates invested in IGEL in 2021. Since then, the company has significantly changed course. For example, IGEL stopped manufacturing its own thin clients to focus entirely on software. In 2025, it acquired Stratodesk, the maker of the competing endpoint OS NoTouch.
From thin client to resilience platform
The foundation is IGEL OS, an immutable, Linux-based operating system. Organizations centrally manage endpoints via the Universal Management Suite (UMS) and the IGEL App Portal. This gives users access to SaaS, DaaS, VDI, enterprise browsers, and other supported applications. IGEL positions this entire solution as the endpoint layer within Zero Trust architectures and SASE.
With IGEL Business Continuity & Disaster Recovery (BC&DR), the company aims to restore access on Windows endpoints affected by ransomware, other cyberattacks, or system failures. One component of this is Emergency Mode, which allows supported Windows machines to boot into IGEL OS. This feature works only if Dual Boot has been pre-installed and licensed. In addition, IGEL applies the same principles to operational technology (OT), for example in the manufacturing industry.
The transaction is expected to close in the first quarter of 2027, subject to regulatory approval. William Blair served as financial advisor to TA and IGEL, while J.P. Morgan advised Vitruvian.